Market Overview

The global natural killer cells therapeutics market reached a size of USD 3.2 Billion in 2024. It is projected to expand to USD 8.6 Billion by 2033, growing at a CAGR of 11.8% during the forecast period of 2025-2033. The market growth is driven primarily by increasing cancer risks and a growing aging population worldwide. This report provides a comprehensive analysis of market dynamics and opportunities.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Natural Killer Cells Therapeutics Market Key Takeaways

• The market size was USD 3.2 Billion in 2024.
• The market is expected to grow at a CAGR of 11.8% during 2025-2033.
• North America is the dominant region, supported by government financial schemes for cancer patients.
• Extensive clinical investments focus on tumor-targeted antibody strategies to reduce risks and toxicities.
• Research centers and institutes hold the largest market share among end users due to their provision of high-quality NK cell reagents and technologies.
• NK cell directed antibodies currently command the largest share within therapeutics.
• Cancer remains the leading application segment driving market growth.

Sample Request Link: https://www.imarcgroup.com/natural-killer-cells-therapeutics-market/requestsample

Market Growth Factors

The rise in cancer cases, infectious diseases, and liver diseases due to sedentary lifestyles, unhealthy dietary habits, and increased air pollution is anticipated to propel the growth of the NK cell therapies market during the forecast period. This is attributed to the rising demand for innovative therapies based on the mechanism of NK cells. The rise in the geriatric population prone to diseases is also propelling market growth.

This wide-ranging investment in clinical research into tumor-targeted antibody approaches that increase precision while avoiding side effects and toxicity has driven a trend towards the development of safer, more effective and potentially more widely applicable NK cell therapies that have in turn attracted wider interest and investment as product development.

The NK cell therapy market may also be spurred by the development of combination therapies, therapies which use NK cells in conjunction with other forms of treatment for improved efficacy. Natural Pharma's drug Lumoxiti targets CD22-positive cancer cells in combination with NK cells. Increasingly, regulatory authorities are supporting the transition of research into the clinic, such as by granting orphan drug designations, for example Ingenium Therapeutics' product for AML.

Market Segmentation

Breakup by Therapeutics:

• NK Cell Therapies
• NK Cell Directed Antibodies: Currently hold the majority market share; these antibodies enhance NK cells' ability to detect and destroy cancer cells. For instance, Affimed's AFM13 bispecific NK cell engager targets CD30 on cancer cells and CD16A on NK cells.

Breakup by Application:

• Cancer: Dominant application segment propelled by increasing need for effective treatments. Fate Therapeutics' FT596, an iPSC-derived NK cell therapy, targets various cancers including B-cell malignancies.
• Gastrointestinal Diseases
• Immunoproliferative Disorders
• Others

Breakup by End User:

• Hospitals
• Research Centers and Institutes: Hold the largest market share; provide high-quality reagents and technologies supporting NK cell research, such as Bio-Techne's Cloudz Human NK Cell Expansion Kit.
• Others

Regional Insights

North America dominates the natural killer cells therapeutics market, driven by government financial support programs for cancer treatment and robust biotechnology advancements. The U.S. cancer immunotherapy market alone projects a CAGR of 10.90% during 2024-2032. Collaborative efforts among biotech companies further bolster this regional market leadership.

Recent Developments & News

In May 2024, Coeptis Therapeutics Holdings, Inc. introduced SNAP-CAR NK cells targeting multiple antigens, enhancing cell therapy versatility. In April 2024, Ingenium Therapeutics received U.S. FDA orphan drug designation for its novel treatment for acute myeloid leukemia. Earlier in January 2024, Indapta Therapeutics, Inc. commenced Phase 1 clinical trials for IDP-023, NK cell therapeutics aimed at multiple myeloma and non-Hodgkin’s lymphoma.

Key Players

• Affimed GmbH
• Bristol-Myers Squibb Company
• Fate Therapeutics
• Fortress Biotech Inc.
• Glycostem Therapeutics
• Innate Pharma S.A.
• Kuur Therapeutics Inc. (Athenex Inc.)
• Nkarta Inc.
• Takeda Pharmaceutical Company Limited
• Ziopharm Oncology Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request For Customization: https://www.imarcgroup.com/request?type=report&id=4214&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302